OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Tang on Metastasis-Directed Radiotherapy Without Systemic Therapy in Oligometastatic ccRCC

April 28th 2025

Chad Tang, MD, discusses outcomes for metastasis-directed radiotherapy without systemic therapy in oligometastatic clear cell renal cell carcinoma.

Dr Trinh on Outcomes for Darolutamide Plus ADT in Black Patients With mHSPC

April 28th 2025

Quoc-Dien Trinh, MD, MBA, discusses outcomes for darolutamide plus ADT in Black patients with metastatic hormone-sensitive prostate cancer.

Dr Ghoreifi on the Feasibility for Consolidative Surgery After Enfortumab Vedotin/Pembrolizumab in Advanced Urothelial Cancer

April 28th 2025

Alireza Ghoreifi, MD, discusses the feasibility of consolidative surgery for advanced urothelial cancer receiving pembrolizumab/enfortumab vedotin.

Dr Jacob on the Potential for TAR-200 to Shift the Treatment Paradigm in NMIBC

April 27th 2025

Joseph Jacob, MD, MCR, discusses how emerging data for TAR-200 could represent a shift in the treatment paradigm for patients with high-risk non–muscle-invasive bladder cancer.

Dr Dinney on the Association Between UGDB and Cretostimogene Grenadenorepvec Response in NMIBC

April 27th 2025

Colin P.N. Dinney, MD, discusses urinary genomic disease burden as a potential biomarker for response to cretostimogene grenadenorepvec in bladder cancer.

Dr Sekeres on Next Steps for Evaluating the Association Between Smoking and MDS

April 25th 2025

Mikkael A. Sekeres, MD, discusses questions that remain unanswered regarding the association between smoking and MDS development and progression.

Dr Cortese on Potential Mechanisms for Improving CLL Outcomes With Venetoclax

April 25th 2025

Matthew Cortese, MD, MPH, discusses the rationale for an analysis of the immunologic activity of venetoclax in patients with chronic lymphocytic leukemia.

Dr Herzberg on Future Research Directions in KRAS-Mutant NSCLC

April 25th 2025

Benjamin Herzberg, MD, discusses unanswered questions regarding the role of KRAS inhibitors for patients with non–small cell lung cancer.

Dr Mouabbi on the Rationale for Early, Serial ESR1 Mutation Testing in HR+ Breast Cancer

April 25th 2025

Jason A. Mouabbi, MD, discusses how ESR1 mutations can cause patients with HR-positive, HER2-negative breast cancer to develop endocrine resistance.

Dr Desai on the Role of Palbociclib in HR+, HER2+ Metastatic Breast Cancer

April 25th 2025

Neelam Desai, MD, discusses the role of a palbociclib-containing regimen in HR-positive, HER2-positive metastatic breast cancer.

Lessions Learned: Advice for the Next Generation of Women in Oncology

April 25th 2025

Drs Mahtani, McCann, and Melody all reflect on advice they'd offer to aspiring female oncologists.

Dr McNall-Knapp on the Efficacy of MEK Inhibition in NF1-Associated PNs

April 24th 2025

Rene Y. McNall-Knapp, MD, discusses the current treatment paradigm for pediatric and adult patients with NF1-associated PNs.

Dr Oberstein on Clinical Applications for Oncodetect in MRD Detection in Solid Tumors

April 24th 2025

Paul E. Oberstein, MD, discusses the clinical applications of the Oncodetect test for molecular residual disease detection in patients with solid tumors.

Dr Ali on the Potential SOC Role of Palbociclib Plus Anti-HER2 and Endocrine Therapy in HER2+ Breast Cancer

April 24th 2025

Azka Ali, MD, discusses the use of palbociclib to overcome resistance to anti-HER2 and endocrine therapies in HER2-positive breast cancer.

Dr McGregor on the Outcomes of an Analysis Evaluating the Optimal Dose of Tivozanib in RCC

April 23rd 2025

Bradley McGregor, MD, highlights the outcomes of an exposure response analysis assessing the optimal dose of tivozanib in patients with RCC.

Dr Randall on the Surgical Management of Low-Grade Chondrosarcoma

April 23rd 2025

R. Lor Randall, MD, FACS, discusses whether patients with low-grade chondosarcomas should undergo intralesional curettage or en bloc resection.

Dr Dumbrava on Targeting TP53 Y220C Mutations in Solid Tumors With Rezatapopt

April 23rd 2025

Ecaterina Dumbrava, MD, discusses early findings of rezatapopt in patients with solid tumors harboring TP53 Y220C mutations.

Dr Ahmed on the Safety Profile of NKTR-255 in Relapsed/Refractory LBCL

April 23rd 2025

Sairah Ahmed, MD, discusses safety data with NKTR-255 in patients with relapsed/refractory large B-cell lymphoma.

Joseph on the Research Behind the Role of Exercise and Supportive Care in Myeloma

April 23rd 2025

Janine Joseph, MS, MBA, discusses the current state of research and future directions for resistance training interventions in patients with multiple myeloma.

Dr Harrison on Factors Influencing Patient Prognosis and Treatment Selection in Myelofibrosis

April 22nd 2025

Claire Harrison, MD, FRCP, FRCPath, discusses factors informing treatment selection for patients with myelofibrosis.